A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients

Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the prostate * Ongoing androgen deprivation therapy with a GnRH analogue or a bilateral orchiectomy * Progressive disease after prior androgen deprivation therapy (medical or surgical castration) * For Expansion Cohort, the patient has no more than two prior chemotherapy regimens with at least one regimen containing docetaxel * For Expansion Cohort, the patient must have measurable lesions by RECIST Exclusion Criteria: * Metastases in the brain * History of another malignancy except for adenocarcinoma of the prostate within the previous 5 years * Use of bicalutamide within 6 weeks prior to study * Radiation therapy within 12 weeks prior to study * Evidence of serious drug hypersensitivity